On this page, you will find different kinds of study results:
• A Lay summary which is a summary of clinical trial results written in an easy-to-understand way.
• A summary of results called synopsis which is written in scientific language. It is prepared for Medicines Agencies and Ethics Committees,
• A scientific publication which presents results for scientists and medical doctors.
219 Results
| Protocol Code |
Study Title |
Active substance/Medical device |
Study Phase |
Therapeutic Area |
| CL3-20098-078 |
Efficacy and safety of agomelatine (25-50 mg/day) for 12 weeks in patients with Generalized Anxiety…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-076 |
Efficacy and safety of 2 doses of agomelatine (10mg, 25mg) given orally in children (from…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-074 |
Efficacy and safety of agomelatine with flexible dose (25 mg/day with blinded potential adjustment at…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-073 |
Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering Major Depressive…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-071 |
Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-070 |
Efficacy and safety of agomelatine oral administration (25 to 50 mg/day) in elderly patients suffering…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-069 |
Efficacy and safety of 3 dose regimens of agomelatine (10, 25, 25-50 mg) versus placebo…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-063 |
Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-062 |
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-060 |
Effects of agomelatine versus escitalopram on emotional experiences in outpatients suffering from Major Depressive Disorder.…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-056 |
Effects of agomelatine (25 to 50 mg/day) on sleep EEG parameters compared to escitalopram in…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-052 |
Efficacy and safety of agomelatine with flexible dose (25 mg/day with potential adjustment at 50…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-051 |
Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-050 |
Long-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-048 |
Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-047 |
Efficacy and safety of agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-046 |
Efficacy of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally on rest/activity…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-045 |
Efficacy and safety of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-20098-041 |
A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg)…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-18886-012 |
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a…
|
TERUTROBAN,
S018886
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-102 |
Effects of ivabradine on plaque burden, morphology and composition in patients with clinically indicated coronary…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-098 |
Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-097 |
Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-083 |
Effects of ivabradine in patients with stable coronary artery disease without clinical heart failure. A…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-078 |
Effects of a 10 or 15 mg single intravenous bolus of ivabradine versus placebo on…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
Servier clinical trials are mainly registered on
EU Clinical Trials Register
The EU Clinical Trials Register contains information on interventional clinical trials on medicines carried out in Europe, which started after 1 May 2004.
SEE MORE
ClinicalTrials.gov
Clinicaltrials.gov is a registry that contains information on clinical studies of human participants carried out around the world.
SEE MORE
ISRCTN registry
The International Standard Randomized Controlled Trial Number (ISRCTN) registry is a primary clinical trial registry recognised by World Health Organization (WHO) and International Committee of Medical Journal Editor (ICMJE) that accepts all clinical research studies.
SEE MORE
